Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Home
/
update
/
details

Myriad Genetics Completes EndoPredict Sale to Eurobio Scientific and Advances International Reorganization

NextEdge Admin

02 Aug 2024

2 min 34 sec

Myriad Genetics, Inc. , a leader in genetic testing and precision medicine, announced the sale of its EndoPredict® business to Eurobio Scientific, a prominent French group in in vitro medical diagnostics and life sciences. This transaction includes a license for Eurobio to sell Prolaris® in vitro diagnostic kits outside the U.S.

In May 2024, Myriad reorganized its International operations to align resources with domestic opportunities while maintaining service for global biopharma partners and patients. The sale of EndoPredict builds on Myriad's efforts to drive profitable growth across its portfolio. Myriad retains the rights to produce and sell EndoPredict in the U.S. as part of Precise™ Oncology Solutions, which includes precision medicine tools for various cancers such as breast, prostate, ovarian, pancreatic, endometrial, and colon cancer.

Paul J. Diaz, President and CEO of Myriad Genetics, stated, “The reorganization of Myriad’s International operations will enable us to continue growing our oncology and biopharma business in Europe and Asia, including Japan, through a more efficient commercial distribution model that reduces organizational complexity and enterprise risk.”

EndoPredict is a prognostic test for breast cancer that predicts the risk of recurrence, helping to identify patients who may safely forgo chemotherapy. Prolaris is a molecular diagnostic test providing personalized information about the aggressiveness of prostate cancer.

Myriad Genetics is dedicated to advancing health and well-being through genetic testing and precision medicine. The company develops genetic tests that assess the risk of disease development or progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and reduce healthcare costs.